Glennon RA, Dukat M (2 May 2023). "Quipazine: Classical hallucinogen? Novel psychedelic?". Australian Journal of Chemistry. 76 (5): 288–298. doi:10.1071/CH22256. ISSN0004-9425.
Cappelli A, Butini S, Brizzi A, Gemma S, Valenti S, Giuliani G, et al. (2010). "The interactions of the 5-HT3 receptor with quipazine-like arylpiperazine ligands: the journey track at the end of the first decade of the third millennium". Curr Top Med Chem. 10 (5): 504–526. doi:10.2174/156802610791111560. PMID20166948.
Rodríguez R, Pardo EG (1971). "Quipazine, a new type of antidepressant agent". Psychopharmacologia. 21 (1): 89–100. doi:10.1007/BF00404000. PMID5567294.
Glennon RA (1996). "Classical Hallucinogens". Pharmacological Aspects of Drug Dependence. Vol. 118. Berlin, Heidelberg: Springer Berlin Heidelberg. p. 343–371. doi:10.1007/978-3-642-60963-3_10. ISBN978-3-642-64631-7.
Glennon RA (1988). "Site-Selective Serotonin Agonists as Discriminative Stimuli". Transduction Mechanisms of Drug Stimuli. Berlin, Heidelberg: Springer Berlin Heidelberg. p. 15–31. doi:10.1007/978-3-642-73223-2_2. ISBN978-3-642-73225-6.
Nakagawasai O, Arai Y, Satoh SE, Satoh N, Neda M, Hozumi M, et al. (January 2004). "Monoamine oxidase and head-twitch response in mice. Mechanisms of alpha-methylated substrate derivatives". Neurotoxicology. 25 (1–2): 223–232. doi:10.1016/S0161-813X(03)00101-3. PMID14697897.
Young R, Glennon RA (1986). "Discriminative stimulus properties of amphetamine and structurally related phenalkylamines". Med Res Rev. 6 (1): 99–130. doi:10.1002/med.2610060105. PMID3512936.
Glennon RA, Rosecrans JA (1981). "Speculations on the mechanism of action of hallucinogenic indolealkylamines". Neurosci Biobehav Rev. 5 (2): 197–207. doi:10.1016/0149-7634(81)90002-6. PMID7022271.
Goudie AJ (September 1985). "Comparative effects of cathinone and amphetamine on fixed-interval operant responding: a rate-dependency analysis". Pharmacol Biochem Behav. 23 (3): 355–365. doi:10.1016/0091-3057(85)90006-1. PMID4048231.
Cappelli A, Butini S, Brizzi A, Gemma S, Valenti S, Giuliani G, et al. (2010). "The interactions of the 5-HT3 receptor with quipazine-like arylpiperazine ligands: the journey track at the end of the first decade of the third millennium". Curr Top Med Chem. 10 (5): 504–526. doi:10.2174/156802610791111560. PMID20166948.
Rodríguez R, Pardo EG (1971). "Quipazine, a new type of antidepressant agent". Psychopharmacologia. 21 (1): 89–100. doi:10.1007/BF00404000. PMID5567294.
Nakagawasai O, Arai Y, Satoh SE, Satoh N, Neda M, Hozumi M, et al. (January 2004). "Monoamine oxidase and head-twitch response in mice. Mechanisms of alpha-methylated substrate derivatives". Neurotoxicology. 25 (1–2): 223–232. doi:10.1016/S0161-813X(03)00101-3. PMID14697897.
Winter JC (1994). "The stimulus effects of serotonergic hallucinogens in animals". NIDA Research Monograph. 146: 157–182. PMID8742798.
Young R, Glennon RA (1986). "Discriminative stimulus properties of amphetamine and structurally related phenalkylamines". Med Res Rev. 6 (1): 99–130. doi:10.1002/med.2610060105. PMID3512936.
Glennon RA, Rosecrans JA (1981). "Speculations on the mechanism of action of hallucinogenic indolealkylamines". Neurosci Biobehav Rev. 5 (2): 197–207. doi:10.1016/0149-7634(81)90002-6. PMID7022271.
Goudie AJ (September 1985). "Comparative effects of cathinone and amphetamine on fixed-interval operant responding: a rate-dependency analysis". Pharmacol Biochem Behav. 23 (3): 355–365. doi:10.1016/0091-3057(85)90006-1. PMID4048231.